FDA
-
-
-
-
-
-
-
Keros Therapeutics Announces Additional Update on the Phase 2 TROPOS Trial
-
-
-
-
-
-
-
Keros Therapeutics (KROS) Presents Clinical Data from KER-050 Program
-
-
-
-
-
-
-
Corrected: Keros Therapeutics to Host Conference Call and Webcast to Provide an Overview of TROPOS, the KER-012 Phase 2 Clinical Trial in Patients with Pulmonary Arterial Hypertension
-
322,240 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

